Trials / Completed
CompletedNCT01148849
Safety Study of MGAH22 in HER2-positive Carcinomas
A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- MacroGenics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if MGAH22 is safe when given by intravenous (IV) infusion to patients with HER2-positive cancer. The study will also evaluate how long MGAH22 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it has an effect on tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | margetuximab | margetuximab |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2022-06-14
- Completion
- 2022-06-14
- First posted
- 2010-06-22
- Last updated
- 2025-02-26
Locations
3 sites across 2 countries: United States, South Korea
Source: ClinicalTrials.gov record NCT01148849. Inclusion in this directory is not an endorsement.